Veeda Clinical IPO is to open on 2025. It is a Mainboard IPO that will raise ₹[.] crores. The Veeda Clinical IPO price band is fixed at ₹[.] with a market lot of [.] Shares.
Veeda Clinical IPO GMP Live Rates day by day with Kostak rates.
| Date | IPO GMP | GMP Trend | Gain |
| 10 Nov | ₹- | – | -% |
Veeda Clinical Research IPO Details
Veeda Clinical IPO Dates
| IPO Open Date: | 2025 |
| IPO Close Date: | 2025 |
| Basis of Allotment: | 2025 |
| Refunds: | 2025 |
| Credit to Demat Account: | 2025 |
| IPO Listing Date: | 2025 |
| IPO Bidding Cut-off Time: | 2025 – 5 PM |
Business Overview
Veeda Clinical Research Limited was established in April 2004, is one of the leading global full-service contract research organizations (“CRO”) in India. The company is involved in offering complete drug development services from pre-clinical testing to clinical trials for new drugs, generics, biosimilars, and medical devices.
Veeda Clinical is involved wide range of services, including (i) Clinical trials (early and late phase), (ii) Healthy volunteer studies like bioavailability and bioequivalence tests, (iii) Pre-clinical and non-clinical testing, and (iv) Biopharma services for large molecule analysis. Founded in 2004, and started its first facility in Ahmedabad, Gujarat, in 2005 with HVS capabilities. Since its incorporation, the company has been growing through expansion and acquisitions to help small, mid-sized, and global pharmaceutical companies.
Veeda Clinical IPO GMP aka Grey Market Premium FAQs:
What is Veeda Clinical IPO GMP Today?
What is Veeda Clinical IPO Expected Returns?
Disclaimer:
- IPO Grey Market Premium (Veeda Clinical IPO GMP) mention is valid for the specific date as mentioned in the header.
- We are not buying and selling IPO forms on IPO Grey Market.
- Kostak Rate is the premium one gets by selling his/her IPO application (in an off-market transaction) to someone else even before allotment or listing of the issue.
- Do not subscribe for IPO by just seeing the premium Price as it may change anytime before listing. Subscribe only considering the fundamentals of the companies.



